A federal judge on Tuesday refused to overturn a court verdict regarding a patent dispute between Thousand Oaks, Calif.-based Amgen, Paris-based Sanofi and Tarrytown, N.Y.-based Regeneron Pharmaceuticals, reports Reuters.
In October 2014, Amgen filed a lawsuit to prevent Sanofi and Regeneron from selling its cholesterol drug Praluent. Amgen alleged Praluent, which Sanofi and Regeneron co-developed, infringed on patents for its own cholesterol-lowering drug Repatha, according to the report.
While a jury found Amgen's patents valid in March 2015, Sanofi and Regeneron filed a motion for U.S. District Judge Sue Robinson to overturn the verdict and order a new trial, Reuters reported. Judge Robinson denied the motion Tuesday.
Damages have yet to be set and it is still unclear whether Sanofi and Regeneron will be barred from selling Praluent. The defendants plan to take the case to the U.S. Federal Circuit Court of Appeals to once again review the patent dispute.
More articles on supply chain:
Morningstar prognosticates on the future of drug pricing, healthcare M&A
5 drugs that made headlines in 2016
Titan Medical appoints new CEO: 6 things to know